公开(公告)号：US11564922B2

公开(公告)日：2023-01-31

申请号：US17732070

申请日：2022-04-28

申请人： AbbVie Inc.

发明人： Aileen L. Pangan ,  Roopal B. Thakkar ,  Steven Jungerwirth ,  Ana Paula Machado De Lacerda ,  Anne M. Robinson ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder ,  Wen Zhou

IPC分类号： A61K31/4985 ,  A61K31/495 ,  A61P1/00 ,  A61K9/00 ,  A61K9/48

摘要： The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.

公开(公告)号：US11607411B2

公开(公告)日：2023-03-21

申请号：US17712008

申请日：2022-04-01

申请人： AbbVie Inc.

发明人： Ana Paula Machado De Lacerda ,  Jose Jeffrey V. Enejosa ,  Aileen L. Pangan ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder ,  Wen Zhou

IPC分类号： A61K31/4985 ,  A61K31/495 ,  A61P1/00 ,  A61K9/00 ,  A61K9/48

摘要： The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.

公开(公告)号：US20220233527A1

公开(公告)日：2022-07-28

申请号：US17712008

申请日：2022-04-01

申请人： AbbVie Inc.

发明人： Ana Paula Machado De Lacerda ,  Jose Jeffrey V. Enejosa ,  Aileen L. Pangan ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder

IPC分类号： A61K31/4985 ,  A61K31/495 ,  A61P1/00 ,  A61K9/00 ,  A61K9/48

摘要： The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.

公开(公告)号：US20220273651A1

公开(公告)日：2022-09-01

申请号：US17732070

申请日：2022-04-28

申请人： AbbVie Inc.

发明人： Aileen L. Pangan ,  Roopal B. Thakkar ,  Steven Jungerwirth ,  Ana Paula Machado De Lacerda ,  Anne M. Robinson ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder

IPC分类号： A61K31/4985 ,  A61K31/495 ,  A61P1/00 ,  A61K9/00 ,  A61K9/48

摘要： The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.